LeBow MBA student Aditya Edakkoth has been chosen as a research fellow for the University City Science Center’s QED Proof-of-Concept Program. Edakkoth is currently working on a project with Xilin Zhao, Ph.D., assistant professor, New Jersey Medical School, and a team of business advisors in the development and marketing of a new therapy for tuberculosis. His duties include working with the team to provide secondary market research, providing recommendations and developing a business plan for the technology.
Edakkoth, who is also president of Net Impact LeBow, says he is trying to glean as much from the experience as possible. “From the time I enrolled for my graduate studies, I have been trying to incorporate myself in the professional environment, where I could apply the concepts that I learned in the classrooms. The QED program is the third voluntary project that I have been chosen for, and so far it has been an interesting experience. I am certain I will be able to learn much from the professionals on my team. My goal is to increase my knowledge of pharmaceutical marketing and so far I believe I am on track.”
The QED program (from the Latin Quod Erat Demonstrandum, meaning that which is demonstrated) is available to academic researchers developing technology with high commercial potential in the life sciences, providing key resources to facilitate the commercial development of these technologies.